Subtype
Breast Carcinoma by Gene Expression Profile
CI-CAN-00004666Explore in graph →
537 active trials6 approved drugs101 evidence items
- NCIt
- C53553
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004666Explore in graph →
Clinical trials
1,299 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (217)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05132582 | A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer(HER2CLIMB-05) | active not recruiting | Phase 3 | 654 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 23 | Sep 29, 2026 | clinicaltrials |
| NCT02954874 | Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer | active not recruiting | Phase 3 | 1,195 | National Cancer Institute (NCI)NIH | 3 | Aug 31, 2026 |
| clinicaltrials |
| NCT06419621 | PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC | active not recruiting | Phase 3 | 392 | Biotheus Inc.INDUSTRY | 1 | Jul 29, 2026 | clinicaltrials |
| NCT02445391 | Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy | active not recruiting | Phase 3 | 415 | ECOG-ACRIN Cancer Research GroupNETWORK | 2 | Jul 27, 2026 | clinicaltrials |
| NCT03975647 | A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer | active not recruiting | Phase 3 | 466 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 20 | Jul 23, 2026 | clinicaltrials |
| NCT06316531 | A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer | active not recruiting | Phase 3 | 274 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06382142 | A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02) | active not recruiting | Phase 3 | 418 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT05552001 | Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer(ISIdE) | active not recruiting | Phase 3 | 96 | UNICANCEROTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT05078047 | Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO(MOIO) | active not recruiting | Phase 3 | 646 | UNICANCEROTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT04457596 | T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial | active not recruiting | Phase 3 | 1,056 | Alliance for Clinical Trials in OncologyOTHER | 3 | Jun 15, 2026 | clinicaltrials |
| NCT05347134 | SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer | active not recruiting | Phase 3 | 254 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT06968585 | A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy(A166) | active not recruiting | Phase 3 | 365 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT02488967 | Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer | active not recruiting | Phase 3 | 782 | NRG OncologyOTHER | 2 | May 6, 2026 | clinicaltrials |
| NCT05705401 | Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer(HERO) | active not recruiting | Phase 3 | 1,300 | NRG OncologyOTHER | 2 | Apr 27, 2026 | clinicaltrials |
| NCT04595565 | Sacituzumab Govitecan in Primary HER2-negative Breast Cancer(SASCIA) | active not recruiting | Phase 3 | 1,332 | GBG Forschungs GmbHOTHER | 7 | Apr 22, 2026 | clinicaltrials |
| NCT05382299 | Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer(ASCENT-03) | active not recruiting | Phase 3 | 623 | Gilead SciencesINDUSTRY | 30 | Apr 6, 2026 | clinicaltrials |
| NCT06519370 | FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer | active not recruiting | Phase 3 | 350 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT03997123 | Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC(CAPItello-290) | active not recruiting | Phase 3 | 923 | AstraZenecaINDUSTRY | 30 | Dec 22, 2025 | clinicaltrials |
| NCT06265428 | A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer | active not recruiting | Phase 3 | 228 | DualityBio Inc.INDUSTRY | 1 | Oct 20, 2025 | clinicaltrials |
| NCT05382286 | Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer(ASCENT-04) | active not recruiting | Phase 3 | 443 | Gilead SciencesINDUSTRY | 28 | Sep 18, 2025 | clinicaltrials |
| NCT04335669 | NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC | active not recruiting | Phase 3 | 325 | Lund University HospitalOTHER | 2 | Sep 12, 2025 | clinicaltrials |
| NCT05346224 | A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer | active not recruiting | Phase 3 | 900 | Shanghai Henlius BiotechINDUSTRY | 4 | Jun 10, 2025 | clinicaltrials |
| NCT03562637 | Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC | active not recruiting | Phase 3 | 575 | OBI Pharma, IncINDUSTRY | 13 | May 9, 2025 | clinicaltrials |
| NCT03168880 | A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly Carboplatin In Women With Large Operable or Locally Advanced, Triple Negative Breast Cancer(TNBC) | active not recruiting | Phase 3 | 720 | Tata Memorial HospitalOTHER_GOV | 1 | Apr 9, 2025 | clinicaltrials |
| NCT04296175 | Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE)(CITRINE) | active not recruiting | Phase 3 | 808 | Fudan UniversityOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT05426486 | A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients | active not recruiting | Phase 2 / Phase 3 | 136 | Caigang LiuOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT03281954 | Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo | active not recruiting | Phase 3 | 1,550 | NSABP Foundation IncNETWORK | 2 | Apr 8, 2024 | clinicaltrials |
| NCT02641847 | TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature | active not recruiting | Phase 2 / Phase 3 | 503 | Fudan UniversityOTHER | 1 | Jan 25, 2024 | clinicaltrials |
Data updated 17 hours agoSource updated Sep 29, 2026source: clinicaltrials